People

People & Governance — Molina Healthcare

A disciplined, professionally-managed turnaround story that just punched itself in the face. The pay-for-performance machine actually worked in 2025 — cash bonuses zeroed, three vintages of PSUs forfeited, a CEO special grant likely worth $0 — but a stockholder-rebuffed retention package, a 53% stock drawdown, and an opening shareholder investigation into medical-cost disclosure have put governance back on the table for the first time in years. Insider conviction is split: one director bought, the chief legal officer sold $3.3M.

Who runs Molina

Five named executive officers, four of whom have run this company together through the entire post-founder era. This is not a founder-led story — the Molina family was removed from operating control in May 2017 and now holds under 2%. It is a Hartford-and-Aetna-style turnaround team that took the helm in November 2017 and converted a near-broken Medicaid plan into a Fortune 155 operator before stumbling on cost trend in late 2025.

The September 2024 decision to fold the Medicaid and Marketplace P&L into the CFO's portfolio compresses the No. 2 and No. 3 jobs into one person. Mark Keim now owns finance, the company's largest operating segment, and Marketplace — an organisational concentration that is rare in the peer group and that materially raises CFO key-man risk.

Compensation — pay-for-performance is on trial, and it just passed the test

The right bar is the one to focus on. In each of the last four years the "actually paid" number — Compensation Committee's mark-to-market view that reflects what the equity is worth on Dec 31 — has fallen further below the headline grant value. In 2025 it went negative: a $15.3M cost to Zubretsky, against a $18.3M nominal grant. That is the system functioning as designed — a 56% drawdown in MOH stock during 2025 chopped tens of millions off in-flight equity. Adjusted EPS of $11.03 came in less than half of the $24.50 threshold guide; this is what triggered the cascading forfeitures below.

Stockholders are not, however, mollified. The 2025 say-on-pay vote drew only 40% support — a stunning rebuke after five straight years averaging over 90%. The trigger was a one-time CEO retention grant made in Fall 2024 with a 2027 single-year adjusted-EPS hurdle of $32 (threshold) / $36 (target). The Compensation Committee has now effectively conceded the special grant will pay zero, but the question remains why it was issued at all without three-year performance averaging.

Cash bonuses are zero across every NEO — the bar's orange slice is invisible because the value is $0. Equity dominates, and that equity is now performance-marked down or forfeited. The $18.3M CEO headline misleads — realized 2025 compensation is closer to $2.1M (salary + perks + dividend equivalents on vested RSAs).

Alignment — better than the headline suggests

Zubretsky personally owns 373,465 shares — roughly 47× his base salary, nearly ten times the required 5× threshold. Keim sits at ~17× (against a 4× requirement). All five NEOs satisfied stock-ownership guidelines as of Dec 31, 2025. The policy further prohibits all pledging and all hedging, and zero shares were pledged. This is genuine skin in the game, not the cosmetic kind.

The institutional cap table reflects a fully widely-held, post-founder company:

Cobalt Capital's Nov 2025 disclosure is the most interesting external signal: a brand-new 115,000-share position taken at $138/share that represents 10.1% of the fund's reportable AUM and is its 4th-largest holding. Concentration of that magnitude in a stock down 55% YTD is a contrarian conviction trade, not an index buy.

Insider trading — mixed, mostly mechanical

The only true open-market purchase in 2026 is Director Richard Zoretic's 800 shares on Feb 12 — small in dollars but the right signal at a depressed price. Everything else is either administrative (quarterly director RSU grants, March equity-vest tax withholding) or share sales: the May 13, 2026 Barlow sale of 17,811 shares at ~$186 ($3.3M) was the largest discretionary disposal and post-dates the first wave of stockholder investigation news. Note: third-party news outlets (Simply Wall St) characterised recent activity as "substantial insider purchases" by the CFO/COO/EVP/CLO; the underlying Form 4s do not support that read — those were RSU vestings, not open-market buys.

Board — independent on paper, aging in practice

The skills mix is appropriate for a Medicaid MCO: deep healthcare operating experience (Wolf, Zoretic, Lockhart, Soistman), audit/finance heft (Orlando, Schapiro, Brasier, Keim's parent — but no overlap on board), and now technology (Grohowski, added 2025). What is thin is independent challenge on cyber, AI/automation, and consumer/digital channels — important as MOH expands telehealth.

The tenure profile is the more pressing issue:

• Three directors are over 12 years tenured (Romney 23, Orlando 21, Wolf 13) — all grandfathered before the 2020 12-year term-limit rule.
• Average age of the nine sitting directors is 70 — older than any of MOH's MCO peers.
• The Board has, to its credit, refreshed methodically: Lockhart (2021), Grohowski (2025), Soistman nominee (2026) — but the long-tenured trio still chair Audit, Comp, and Corporate Governance & Nominating, the three most consequential committees.

Red flags

Related-party transactions — trivially small

The only disclosed related-party transaction in 2025 is the continuing employment of George Romney, son of Director Ronna Romney, at an annual base salary of approximately $157,590. The Board's Corporate Governance & Nominating Committee ratified the arrangement. At ~0.0003% of payroll this is housekeeping, not a governance issue — but it does fit the pattern of long-standing family relationships on a long-tenured board.

Workforce sentiment — adequate, not impressive

Glassdoor: 3.3 stars (2,747 reviews), 50% would recommend, CEO approval 59%. Senior management scores the lowest sub-rating at 2.9. Indeed: 2,528 reviews. CEO pay ratio of 228:1 is high but not out of line with insurance industry medians (UnitedHealth ~340:1, Centene ~315:1). The ESOP-style shelf registration filed in late 2025 for 1.5M shares (~$264M at then-price) extends ownership beyond the C-suite — a constructive alignment move.

Verdict

Letter grade: B-. Genuine alignment (real CEO ownership, no pledging/hedging, clawback active), a functioning pay-for-performance machine (zero bonuses paid, three vintages of PSUs forfeited), and an independent board with relevant operating credentials. Offset by a long-tenured trio chairing the consequential committees, a Fall 2024 retention grant that broke a decade of stockholder goodwill, and a fresh disclosure investigation tied to the cost-trend miss.

The team that turned this company around starting in 2017 is still here, still has its money in the stock, and is being mechanically punished for 2025. The question for buy-side investors is whether one bad cost-trend year is a turnaround setback (in which case this management is still your best bet) or a credibility-on-disclosure event (in which case the investigation matters more than the comp). The next twelve months will resolve that.